Opportunity
Federal Register #337-TA-1519
Investigation of Melanoma Predictive and Prognostic Tests and Components
Buyer
U.S. International Trade Commission
Posted
August 27, 2026
Identifier
337-TA-1519
NAICS
541990
This opportunity involves a government investigation into alleged unfair trade practices concerning melanoma predictive and prognostic tests and their components. - Government Buyer: - U.S. International Trade Commission - OEMs and Vendors Mentioned: - Castle Biosciences, Inc. (complainant) - SkylineDx Holding B.V. - SkylineDx USA, Inc. - Qiagen GmbH - QIAGEN LLC - Products/Services Requested: - Melanoma predictive and prognostic CPGEP tests - Related test components - No specific part numbers or quantities provided - Unique or Notable Requirements: - Investigation focuses on alleged violations of section 337 of the Tariff Act of 1930 - Issues cited include unfair competition and false/misleading advertising - Potential outcomes include limited exclusion orders and cease and desist orders - No procurement or purchase activity; this is an investigative action
Description
A complaint was filed with the U.S. International Trade Commission on July 10, 2026, by Castle Biosciences, Inc. The complaint alleges violations related to the importation or sale of certain melanoma predictive and prognostic tests and components thereof, citing unfair competition and false and misleading advertising. The complainant requests an investigation and the issuance of a limited exclusion order and cease and desist orders. The investigation aims to determine if there is a violation of section 337 of the Tariff Act of 1930 regarding these products.